<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03866512</url>
  </required_header>
  <id_info>
    <org_study_id>250839</org_study_id>
    <nct_id>NCT03866512</nct_id>
  </id_info>
  <brief_title>Forearm Immobilization, Metabolic Health, and Muscle Loss</brief_title>
  <official_title>The Impact of Acipimox and Salbutamol Supplementation on the Development of Insulin Resistance and Anabolic Resistance During Forearm Immobilization in Healthy, Young Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Exeter</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wellcome Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Exeter</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study will investigate the impact of altered substrate availability on muscle
      atrophy, insulin sensitivity and muscle protein synthesis following short-term forearm
      immobilization
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thirty-six healthy young volunteers will undergo 2 days of forearm immobilization combined
      with ingestion of one of two drug or placebo. Before and after immobilization, they will
      receive a stable isotope tracer infusion (5.5 h) combined with repeated blood and muscle
      sampling under insulin clamp conditions, in order to measure insulin sensitivity and muscle
      protein synthesis in the fasted and fed state.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2019</start_date>
  <completion_date type="Anticipated">January 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-blind study design</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Forearm glucose uptake</measure>
    <time_frame>During the steady-state phase of the insulin clamp (i.e. last 30 min)</time_frame>
    <description>Insulin sensitivity, measured as forearm glucose uptake, under hyperinsulinaemic-euglycaemic conditions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Muscle protein synthesis</measure>
    <time_frame>In the fasted state (30 min before starting insulin clamp), and during the steady-state phase of the insulin clamp (i.e. last 30 min)</time_frame>
    <description>Muscle protein synthesis, measured as using the arteriovenous-venous method, via stable isotope tracer infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forearm muscle volume</measure>
    <time_frame>Following cast application, and immediately after 2 days of forearm immobilizaiton</time_frame>
    <description>Forearm muscle volume measured via MRI</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Acipimox ingestion during immobilization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral ingestion of Acipimox during 2 days of forearm immobilization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B-agonist during immobilization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral ingestion of salbutamol during 2 days of forearm immobilization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo ingestion during immobilization</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral ingestion of a placebo 2 days of forearm immobilization</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Forearm immobilization</intervention_name>
    <description>Two days of forearm immobilization</description>
    <arm_group_label>Acipimox ingestion during immobilization</arm_group_label>
    <arm_group_label>B-agonist during immobilization</arm_group_label>
    <arm_group_label>Placebo ingestion during immobilization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females 18-40 years of age

          -  Body mass index between 18 and 27

        Exclusion Criteria:

          -  Any diagnosed metabolic impairment (e.g. type 1 or 2 diabetes)

          -  Any diagnosed cardiovascular disease

          -  Hypertension (≥140 mmHg systolic and/or ≥90 mmHg diastolic)

          -  Chronic use of any prescribed or over the counter pharmaceuticals (excluding oral
             contraceptives and contraceptive devices)

          -  Regular use of nutritional supplements

          -  Metallic implants

          -  A personal or family history of thrombosis, epilepsy, seizures or schizophrenia

          -  Any previous motor disorders

          -  Any known disorders in lipid metabolism

          -  Any known disorders in muscle metabolism

          -  Known allergy for Acipimox, beta agonist, or other substances in the tablets

          -  Known sensitivity for sympathomimetic drugs

          -  Known hypokalaemia

          -  Presence of an ulcer in the stomach or gut and/or strong history of indigestion

          -  Known severe kidney problems

          -  Pregnancy

          -  Unable to give consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marlou Dirks, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Exeter</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marlou Dirks, PhD</last_name>
    <phone>+441392725496</phone>
    <email>m.dirks@exeter.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Royal Exeter &amp; Devon NHS Foundation Trust</name>
      <address>
        <city>Exeter</city>
        <state>Devon</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marlou Dirks, PhD</last_name>
      <phone>+441392725496</phone>
      <email>m.dirks@exeter.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>February 28, 2019</study_first_submitted>
  <study_first_submitted_qc>March 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2019</study_first_posted>
  <last_update_submitted>June 3, 2019</last_update_submitted>
  <last_update_submitted_qc>June 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

